100 related articles for article (PubMed ID: 12458324)
1. Therapeutic vaccines against HPV16-associated tumors. Minireview.
Bubeník J
Neoplasma; 2002; 49(5):285-9. PubMed ID: 12458324
[TBL] [Abstract][Full Text] [Related]
2. Animal models for development of therapeutic HPV16 vaccines (review).
Bubeník J
Int J Oncol; 2002 Jan; 20(1):207-12. PubMed ID: 11743666
[TBL] [Abstract][Full Text] [Related]
3. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic uterine-cervix cancer vaccines in humans.
Gariglio P; Benitez-Bribiesca L; Berumen J; Alcocer JM; Tamez R; Madrid V
Arch Med Res; 1998; 29(4):279-84. PubMed ID: 9887543
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins.
Pozzi E; Basavecchia V; Zanotto C; Pacchioni S; Morghen Cde G; Radaelli A
J Virol Methods; 2009 Jun; 158(1-2):184-9. PubMed ID: 19428588
[TBL] [Abstract][Full Text] [Related]
7. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
8. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Mahdavi A; Monk BJ
Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
[TBL] [Abstract][Full Text] [Related]
9. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins.
Yugawa T; Kiyono T
Rev Med Virol; 2009 Mar; 19(2):97-113. PubMed ID: 19156753
[TBL] [Abstract][Full Text] [Related]
11. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
12. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins.
Narisawa-Saito M; Kiyono T
Cancer Sci; 2007 Oct; 98(10):1505-11. PubMed ID: 17645777
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Subbaramaiah K; Dannenberg AJ
Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
[TBL] [Abstract][Full Text] [Related]
14. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
Uversky VN; Roman A; Oldfield CJ; Dunker AK
J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
[TBL] [Abstract][Full Text] [Related]
15. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
16. Notch1 can contribute to viral-induced transformation of primary human keratinocytes.
Lathion S; Schaper J; Beard P; Raj K
Cancer Res; 2003 Dec; 63(24):8687-94. PubMed ID: 14695182
[TBL] [Abstract][Full Text] [Related]
17. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
[TBL] [Abstract][Full Text] [Related]
18. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
[TBL] [Abstract][Full Text] [Related]
19. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
20. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
